FilingReader Intelligence

Anges and Boehringer Ingelheim begin HGF gene therapy manufacturing partnership

August 20, 2025 at 12:04 PM UTCBy FilingReader AI

Anges and Boehringer Ingelheim have signed a contract for development and manufacturing of HGF gene therapy's active pharmaceutical ingredient. The collaboration, spanning 20 years for clinical trial supplies, aims to accelerate regulatory approval.

Boehringer Ingelheim's BioXcellence will manufacture the active ingredient using proprietary microbial technology at their Vienna facility.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

TSE:4563Tokyo Stock Exchange

News Alerts

Get instant email alerts when Anges publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →